Affinage

ANXA2

Annexin A2 · UniProt P07355

Length
339 aa
Mass
38.6 kDa
Annotated
2026-04-28
100 papers in source corpus 52 papers cited in narrative 53 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ANXA2 is a calcium-dependent phospholipid-binding protein that functions as a multivalent signaling scaffold linking membrane dynamics, signal transduction, and cytoskeletal remodeling to cell proliferation, migration, and epithelial-mesenchymal transition. Src-family kinases phosphorylate ANXA2 at Tyr23/Tyr24—facilitated by scaffolds including Rack1, RalA, and the EphA2–YES1 axis—enabling ANXA2 to bind and activate STAT3, ERK1/2, NF-κB, FAK/AKT, and Wnt/β-catenin pathways, while its protein stability is regulated by E3 ligases (NEDD4L, TRIM65) and deubiquitinases (USP4), and its transcription is controlled by p-STAT3, ETV4, and H4K16 acetylation via MOF (PMID:28470457, PMID:31113450, PMID:33941853, PMID:35977942, PMID:40185997, PMID:38317006, PMID:36324154). At the cell surface, the ANXA2/S100A10 heterotetramer serves as a plasminogen receptor that promotes plasmin generation and additionally facilitates viral assembly and replication for HIV-1, EV71, and influenza A, while intracellularly ANXA2 promotes autophagy through MTORC2-dependent HSF1 activation of ATG7 transcription and is itself a direct binding target of bleomycin at Glu139, whose engagement impedes TFEB-mediated autophagic flux (PMID:34944416, PMID:19325895, PMID:34196914, PMID:38290972, PMID:29172997). ANXA2 also regulates cytoskeletal organization, small GTPase activity, and actin bundling at cell–cell junctions to control epithelial polarity and cell motility (PMID:25344575, PMID:27060670).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2000 Low

    The structural basis of the ANXA2–S100A10 heterotetramer was modeled, establishing that the core interaction is primarily electrostatic—a foundation for understanding the functional AIIt complex.

    Evidence Computational docking and cryo-EM density comparison of the (Anx2)₂(p11)₂ complex

    PMID:11108962

    Open questions at the time
    • No experimental mutagenesis validation of predicted electrostatic contacts
    • Functional consequences of disrupting specific interface residues untested
  2. 2009 Medium

    ANXA2 was shown to interact with HIV-1 Gag at PIP2-containing lipid raft domains and promote viral production, establishing ANXA2 as a host factor for viral assembly at membranes.

    Evidence Bimolecular fluorescence complementation in 293T cells with viral titer measurement

    PMID:19325895

    Open questions at the time
    • No loss-of-function (knockdown) complement to overexpression data
    • Mechanism by which ANXA2 enhances Gag processing not defined
  3. 2012 Medium

    ANXA2 overexpression was linked to ERK1/2 activation and cyclin D1/c-myc upregulation, providing an initial signaling axis connecting ANXA2 to proliferation.

    Evidence ANXA2 overexpression in MCF-7 cells with Western blot and in vitro/in vivo functional assays

    PMID:22452352

    Open questions at the time
    • Overexpression-only study; no reciprocal loss-of-function at this stage
    • Direct versus indirect ERK activation not resolved
  4. 2014 High

    ERG was identified as a transcriptional repressor of ANXA2, and loss of ANXA2 was shown to disrupt actin bundling, epithelial polarity, and small GTPase (CDC42/RHOA) activity—linking ANXA2 to cytoskeletal regulation and EMT.

    Evidence ChIP showing ERG occupancy at the ANXA2 promoter, subcellular imaging, and GTPase activity assays in prostate cancer models

    PMID:25344575

    Open questions at the time
    • Whether ERG-mediated repression operates in non-prostate contexts unknown
    • Structural basis of ANXA2 regulation of CDC42/RHOA not defined
  5. 2015 High

    ANXA2 was established as a direct STAT3-binding partner that enhances STAT3 transcriptional activity, positioning STAT3 as the key downstream effector linking ANXA2 to EMT and proliferation.

    Evidence Reciprocal Co-IP, RNAi knockdown with migration/invasion assays, and in vivo metastasis model in breast cancer

    PMID:26253946 PMID:26307676

    Open questions at the time
    • Binding interface between ANXA2 and STAT3 not structurally characterized
    • Whether STAT3 activation requires ANXA2 phosphorylation was not yet resolved
  6. 2017 High

    Tyr23 phosphorylation by Src was shown to be required for ANXA2–STAT3 binding and activation, resolving the dependence of the ANXA2–STAT3 axis on a specific post-translational modification; concurrently, Rack1 was identified as the scaffold mediating the Src–ANXA2 interaction.

    Evidence Tyr23F phospho-mutant rescue experiments with Co-IP and functional assays; Rack1 knockdown and Src inhibitors in drug-resistant breast cancer cells

    PMID:27754360 PMID:28470457 PMID:31113450

    Open questions at the time
    • Structural basis of the Rack1–Src–ANXA2 ternary complex not resolved
    • Relative contributions of Tyr23 versus Tyr24 across tissues unclear
  7. 2017 Medium

    Multiple non-coding RNAs and growth factor axes were shown to regulate ANXA2 expression and phosphorylation: lncRNA-MUF activates Wnt/β-catenin via ANXA2, while HGF/IGF-1 signaling increases ANXA2 phosphorylation to drive EMT and drug resistance.

    Evidence RNA pulldown, siRNA knockdown, proteomics, dual receptor inhibition, in vitro/in vivo assays across HCC, breast cancer, and NSCLC

    PMID:28947421 PMID:29253515

    Open questions at the time
    • Direct RNA-binding domains on ANXA2 for lncRNA-MUF not mapped
    • Relative importance of HGF vs IGF-1 arms for ANXA2 phosphorylation not dissected
  8. 2017 Medium

    ANXA2 repeat-1 domain was shown to bind PCSK9 and inhibit PCSK9-mediated LDLR degradation, with the V98L coding SNP associated with higher LDL-C in humans—extending ANXA2 function to lipid metabolism.

    Evidence Allele-specific binding assay, reporter gene assay, genetic association in NPHSII and UCLEB cohorts

    PMID:28456096

    Open questions at the time
    • Mechanism by which ANXA2 blocks PCSK9–LDLR interaction not structurally resolved
    • Functional significance of V98L not confirmed by in vivo models
  9. 2018 High

    ANXA2 was identified as a direct molecular target of bleomycin at Glu139; drug binding impedes TFEB-mediated autophagic flux, establishing a mechanism for bleomycin-induced pulmonary fibrosis and revealing ANXA2 as a regulator of autophagy.

    Evidence Chemical proteomics, CRISPR-Cas9 E139A mutagenesis, Anxa2 knockout mice, autophagic flux assays

    PMID:29172997

    Open questions at the time
    • How ANXA2–bleomycin binding mechanistically blocks TFEB nuclear translocation not fully defined
    • Whether other annexin family members share bleomycin sensitivity unknown
  10. 2018 Medium

    TRIM65 was identified as an E3 ligase that ubiquitinates and degrades ANXA2, with ANXA2 degradation paradoxically promoting EMT in bladder cancer—revealing that ubiquitin-mediated turnover of ANXA2 can have context-dependent oncogenic effects.

    Evidence Ubiquitination assays, Co-IP, functional KD/OE in vitro and in vivo

    PMID:30075204

    Open questions at the time
    • Specific ubiquitination sites and chain types for TRIM65-mediated degradation not identified
    • Single-lab finding; context-dependent EMT promotion versus suppression needs clarification
  11. 2019 High

    Ahnak was shown to scaffold an ANXA2/S100A10 complex with L-type voltage-gated calcium channels in neurons, establishing a non-cancer physiological role for the AIIt complex in regulating neuronal calcium currents.

    Evidence Ahnak knockout mice (constitutive and cell-type selective), Co-IP, electrophysiology

    PMID:30760886

    Open questions at the time
    • Whether ANXA2 directly contacts the VGCC β-subunit or acts only via S100A10 not resolved
    • Role of ANXA2 Tyr phosphorylation in VGCC regulation untested
  12. 2021 High

    The ANXA2/S100A10 heterotetramer was consolidated as a cell-surface plasminogen receptor regulated during EMT and by oncogenes (SRC, RAS, HIF1α, PML-RAR), synthesizing decades of work into a unified model of AIIt function in fibrinolysis.

    Evidence Review synthesizing biochemical reconstitution, Co-IP, and cell surface binding assays from multiple labs

    PMID:34944416

    Open questions at the time
    • Structural resolution of AIIt–plasminogen complex lacking
    • In vivo conditional AIIt disruption models limited
  13. 2021 High

    EphA2–YES1 was identified as an alternative kinase axis phosphorylating ANXA2 at Tyr24 (distinct from Src/Tyr23), leading to nuclear translocation and invasion in gastric cancer, broadening the upstream kinase repertoire.

    Evidence Tyr24F phospho-mutant rescue, Co-IP, in vivo mouse models

    PMID:33941853

    Open questions at the time
    • Whether Tyr23 and Tyr24 phosphorylation are functionally redundant or additive not resolved
    • Nuclear targets of ANXA2 after Tyr24-mediated translocation not identified
  14. 2022 High

    NEDD4L was identified as an E3 ligase degrading ANXA2 via its Annexin-1 domain, while lncRNA LINC00941 stabilizes ANXA2 by competitively blocking NEDD4L binding—activating FAK/AKT signaling in pancreatic cancer.

    Evidence RNA pulldown, MS, RIP, Co-IP/MS, domain mapping, ubiquitination assays

    PMID:35977942

    Open questions at the time
    • Whether NEDD4L-mediated degradation uses K48 or K63 linkage not specified
    • Generalizability of LINC00941 decoy mechanism beyond pancreatic cancer untested
  15. 2022 High

    RalA was shown to scaffold ANXA2 with Src to promote Tyr23 phosphorylation and ERK1/2 activation, driven by FOXD1-dependent RalA transcription—identifying a second scaffolding mechanism parallel to Rack1.

    Evidence GST-pulldown, Co-IP, ChIP-seq, CUT&Tag-seq, in vivo CTC quantification, ERK inhibitor rescue

    PMID:36229838

    Open questions at the time
    • Whether Rack1 and RalA operate redundantly or in distinct contexts not tested
    • Direct versus indirect effect of RalA-GTP on ANXA2–Src interaction not dissected
  16. 2024 High

    A comprehensive post-translational modification map emerged: USP4 deubiquitinates ANXA2 by cleaving both K48 and K63 chains, with K63-linked ubiquitination at K28 mediating Tyr24 phosphorylation and K10 acetylation enhancing USP4 binding; ADAM8 phosphorylates Ser26 to regulate mTOR and autophagy; FBXW10 promotes K63-linked polyubiquitination for membrane translocation and KRAS/MEK/ERK activation.

    Evidence Linkage-specific ubiquitination assays, site-directed mutagenesis (K28, K10, Ser26), Co-IP/MS, membrane fractionation, in vivo models across glioblastoma, HCC, and cardiac repair contexts

    PMID:37277019 PMID:39097092 PMID:40185997

    Open questions at the time
    • Interplay between K63-ubiquitination, acetylation, and tyrosine phosphorylation on the same ANXA2 molecule not studied in cis
    • Structural basis for how K63-Ub at K28 enables Tyr24 phosphorylation unknown
  17. 2024 High

    ANXA2 transcription was placed under epigenetic control: MOF-mediated H4K16 acetylation at the ANXA2 promoter (stabilized by USP10 deubiquitination of MOF) drives ANXA2 expression and Wnt/β-catenin signaling; separately, p-STAT3 and ETV4 directly bind the ANXA2 promoter to activate transcription, and XAB2 was identified as an additional transcriptional activator.

    Evidence ChIP/ChIP-Seq for STAT3, ETV4, and H4K16ac at ANXA2 promoter; luciferase reporters; deubiquitination assays; in vivo models

    PMID:34347084 PMID:36324154 PMID:38317006 PMID:40069750

    Open questions at the time
    • How these multiple transcriptional inputs are integrated at the ANXA2 promoter in a single cell type unclear
    • Whether H4K16ac and STAT3 binding are cooperative or independent not tested
  18. 2024 High

    ANXA2 was shown to drive autophagy independently of bleomycin: ANXA2 activates MTORC2-dependent HSF1 phosphorylation, which transcriptionally induces ATG7 to promote autophagy and chemoresistance in triple-negative breast cancer.

    Evidence ChIP for HSF1 at ATG7 promoter, MTORC2 inhibition, autophagic flux assay, TNBC xenograft model

    PMID:38290972

    Open questions at the time
    • How ANXA2 activates MTORC2 mechanistically is not defined
    • Whether Hsp70-mediated stabilization of ANXA2 is specific to TNBC unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: the structural basis of ANXA2 interactions with STAT3, KRAS, and plasminogen; how multiple PTMs (Tyr23/24, Ser26, K28-Ub, K10-Ac) are coordinated on the same molecule; the physiological versus pathological balance of ANXA2's roles in autophagy, fibrinolysis, and inflammation; and whether ANXA2 has intrinsic enzymatic activity or functions purely as a scaffold.
  • No co-crystal structure of ANXA2 with any signaling partner
  • No reconstituted system testing combinatorial PTM effects
  • In vivo conditional ANXA2 knockout phenotyping in non-cancer contexts remains limited

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 6 GO:0008289 lipid binding 3 GO:0098772 molecular function regulator activity 3 GO:0008092 cytoskeletal protein binding 2
Localization
GO:0005886 plasma membrane 4 GO:0005634 nucleus 2 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 9 R-HSA-1643685 Disease 4 R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-9612973 Autophagy 3 R-HSA-109582 Hemostasis 1
Partners
KRASNEDD4LRACK1S100A10SRCSTAT3USP4YES1
Complex memberships
ANXA2/S100A10 (AIIt) heterotetramerAhnak/S100A10/ANXA2/VGCC complexRack1/Src/ANXA2 scaffold complex

Evidence

Reading pass · 53 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 Anxa2 directly binds to STAT3 and enhances its transcriptional activity, thereby promoting EGF-induced epithelial-mesenchymal transition (EMT) in breast cancer cells in a STAT3-dependent manner. Co-immunoprecipitation, knockdown (RNAi), in vitro migration/invasion assays, in vivo metastasis model Oncotarget High 26307676
2017 Tyr23 phosphorylation of Anxa2 by Src-family kinases is required for Anxa2 to bind and enhance STAT3 activation in response to IL-6, leading to increased cyclin D1 and MMP2/9 expression, and promoting breast cancer proliferation and invasion. Co-immunoprecipitation, phospho-mutant (Tyr23F) rescue experiments, Western blot, in vitro and in vivo functional assays Breast cancer research and treatment High 28470457
2019 Rack1 acts as a scaffold protein that mediates the interaction between Src and Anxa2, facilitating Anxa2 Tyr23 phosphorylation by Src kinase and promoting invasion and metastasis in drug-resistant breast cancer cells. Co-immunoprecipitation, small interfering RNA knockdown, small molecule inhibitors, in vivo metastasis models Breast cancer research : BCR High 31113450
2013 P-glycoprotein (P-gp) physically associates with Anxa2 and promotes invasion of multidrug-resistant breast cancer cells by modulating tyrosine phosphorylation of Anxa2 through Src kinase. Co-immunoprecipitation, P-gp modulators/MDR1 knockdown, phosphorylation assays, invasion assays Biochemical pharmacology Medium 24239898
2016 Rack1 mediates the binding of P-gp to Anxa2 and Src, and regulates P-gp activity required for adriamycin-induced Anxa2 phosphorylation and Erk1/2 activation in MDR breast cancer cells. Co-immunoprecipitation coupled with LC-MS/MS, Rack1 knockdown, P-gp activity assays International journal of molecular sciences Medium 27754360
2021 EphA2 activates YES1 which phosphorylates ANXA2 at Tyr24, leading to ANXA2 activation and increased nuclear distribution in gastric cancer cells, promoting invasion and metastasis. Co-immunoprecipitation, phospho-mutant (Tyr24F) rescue experiments, KD/OE functional assays, in vivo mouse models Oncogene High 33941853
2018 TRIM65 promotes ubiquitination and degradation of ANXA2, modulating cytoskeleton rearrangement and inducing EMT to enhance invasion in bladder cancer cells. In vitro and in vivo functional assays, ubiquitination assays, co-IP Cancer letters Medium 30075204
2018 ANXA2 is a direct binding target of bleomycin; binding occurs at Glu139 of ANXA2, and this interaction impedes TFEB-mediated autophagic flux, leading to pulmonary fibrosis. CRISPR-Cas9-engineered ANXA2-E139A mutation abolishes bleomycin binding and activates autophagic flux. Chemical proteomics, in vitro binding assay, CRISPR-Cas9 mutagenesis (E139A), anxa2 knockout mice, autophagic flux assays Autophagy High 29172997
2017 lncRNA-MUF binds ANXA2 and activates Wnt/β-catenin signaling and EMT in hepatocellular carcinoma cells. RNA-protein pulldown, lncRNA knockdown/overexpression, EMT marker Western blot, in vivo tumorigenesis Cancer research Medium 28947421
2019 Ahnak scaffolds a protein complex containing p11 (S100A10) and Anxa2 with the L-type voltage-gated calcium channel (VGCC); Ahnak C-terminal region scaffolds the β subunit of VGCC and the p11/Anxa2 complex, and this interaction is required for cell surface expression of the α1 subunit and L-type calcium current in neurons. Co-IP, Ahnak knockout mice (constitutive and cell-type selective), electrophysiology (calcium current measurement), confocal microscopy Molecular psychiatry High 30760886
2000 The (Anx2)2(p11)2 heterotetramer complex model shows that the interaction between Anx2 core and p11 (S100A10) is primarily electrostatic, stabilized through charged residues, based on structural docking and cryo-electron microscopy density comparison. Computational docking, cryo-electron microscopy density comparison Biochimica et biophysica acta Low 11108962
2009 Annexin 2 (Anx2) interacts with HIV-1 Gag at phosphatidylinositol (4,5) bisphosphate-containing lipid raft membrane domains and promotes HIV-1 Gag processing and viral production. Bimolecular fluorescence complementation (BiFC) in 293T cells, Anx2 overexpression, viral titer measurement PloS one Medium 19325895
2017 ANXA2 interacts with influenza A H5N1 NS1 protein in the cell cytoplasm; ANXA2 overexpression significantly increases H5N1 virus titers, while siRNA knockdown inhibits viral protein expression and reduces progeny virus titer. Co-immunoprecipitation, confocal co-localization, siRNA knockdown, viral titer measurement BMC microbiology Medium 28893180
2021 ANXA2 interacts with EV71 3D polymerase via its annexin domain and with PI4KB; ANXA2 promotes PI4P formation and assembly of the viral RNA replication complex (3D polymerase, PI4KB, ANXA2) at replication organelles, facilitating EV71 replication. Co-immunoprecipitation, ANXA2 knockout cells, PI4P level measurement, domain mapping Virologica Sinica Medium 34196914
2012 Upregulation of Anxa2 promotes proliferation and invasion of MCF-7 breast cancer cells by increasing expression of c-myc and cyclin D1 via activation of Erk1/2 signaling. Anxa2 overexpression, Western blot for downstream signaling, in vitro and in vivo functional assays Cell proliferation Medium 22452352
2015 RNAi-mediated Anxa2 silencing inhibits breast cancer cell proliferation by decreasing cyclin D1 levels through a STAT3-dependent pathway downstream of EGFR signaling. siRNA knockdown, cell cycle analysis, Western blot for STAT3 phosphorylation and cyclin D1 Breast cancer research and treatment Medium 26253946
2015 Ebp1 is an Anxa2-interacting protein (identified by Co-IP/LC-MS/MS interactome) that negatively regulates Anxa2 protein levels; Ebp1 knockdown increases Anxa2, cyclin D1, and p-Erk1/2, enhancing cancer cell proliferation and invasion. Co-immunoprecipitation coupled with LC-MS/MS, siRNA knockdown, Western blot, functional invasion assays Molecular and cellular endocrinology Medium 25917452
2018 TGF-β induces upregulation of ANXA2 and EMT in colorectal cancer cells; ANXA2 silencing hinders TGF-β-induced invasiveness, and the Src/ANXA2/STAT3 pathway mediates this EMT process. ANXA2 siRNA knockdown, Src/STAT3 inhibitors, Western blot for EMT markers, invasion assays Scientific reports Medium 30050103
2017 ANXA2 promotes EGF-induced EMT in breast cancer via the HGF/IGF-1 axis; CAFs increase ANXA2 expression and phosphorylation through HGF/c-met and IGF-1/IGF-1R receptor activation, and ANXA2 knockdown reverses EMT and gefitinib resistance. Proteomics identification, siRNA knockdown, in vitro and in vivo functional assays, dual receptor inhibition Biochimica et biophysica acta. Molecular basis of disease Medium 29253515
2019 S100A11 interacts with ANXA2 and reduces its ubiquitination and degradation, stabilizing ANXA2, and activates NF-κB signaling; NF-κB in turn regulates S100A11 transcription, forming a positive feedback loop in glioblastoma. Co-immunoprecipitation, ubiquitination assay, siRNA knockdown, luciferase reporter, in vivo orthotopic xenograft Journal of cellular and molecular medicine Medium 31430050
2022 LINC00941 (nucleotides 500–1390) binds to the Annexin 1 domain of ANXA2, acting as a decoy that prevents NEDD4L (an E3 ubiquitin ligase) from binding the same domain and degrading ANXA2, thereby stabilizing ANXA2 and activating FAK/AKT signaling to promote pancreatic cancer proliferation and metastasis. RNA pulldown, mass spectrometry, RIP, Co-IP/MS, domain mapping, ubiquitination assays Cell death & disease High 35977942
2018 LUCAT1 lncRNA inhibits phosphorylation of ANXA2, thereby reducing ANXA2-S100A10 heterotetramer (AIIt) degradation, which accelerates secretion of plasminogen into plasmin and activates metalloprotease proteins to promote HCC metastasis. RNA pulldown, Western blot (phosphorylation), functional KD/OE assays Journal of cellular and molecular medicine Medium 30588744
2021 The ANXA2/S100A10 (AIIt) heterotetrameric complex functions as a cell-surface plasminogen receptor that both promotes plasminogen binding and regulates plasmin formation and destruction; AIIt is regulated during EMT and activated by oncogenes such as SRC, RAS, HIF1α, and PML-RAR, and epigenetically by DNA methylation. Review of biochemical reconstitution, co-IP, cell surface binding assays from multiple primary studies cited therein Biomolecules High 34944416
2021 S100A10/AnxA2 complex mediates exocytosis of HBV virions from trophoblast cells; knockdown of either AnxA2 or S100A10 reduces exo-virus in transwell assay, and the complex co-localizes with autophagosome marker LC3 during HBV transcytosis. siRNA knockdown, Transwell assay, co-localization (confocal), immunohistochemistry Laboratory investigation Medium 34645932
2011 ANXA2 protein promotes monocyte migration across an endothelial barrier in vitro, suggesting that elevated ANXA2 in peripheral blood monocytes stimulates their migration to bone resorption surfaces where they differentiate into osteoclasts. Quantitative proteomics (LC-nano-ESI-MSE), in vitro transendothelial migration assay, mRNA and protein validation Molecular & cellular proteomics : MCP Medium 21817168
2017 SMN-dependent axonal localization of Anxa2 mRNA requires a G-rich motif in the 3'UTR; mutations in this motif abolish axonal targeting of Anxa2 reporter mRNAs, and SMN depletion restricts Anxa2 mRNA to the cell body. Reporter mRNA localization assay in differentiated NSC-34 motor neuron-like cells, mutagenesis of G-rich motif, SMN knockdown RNA (New York, N.Y.) Medium 28258160
2023 FBXW10 promotes K63-linked ANXA2 polyubiquitination in a process requiring S6K1-mediated phosphorylation; activated ANXA2 translocates from cytoplasm to cell membrane, binds KRAS, and activates the MEK/ERK pathway to drive HCC proliferation and lung metastasis. Ubiquitination assays (K63-linkage specific), Co-IP, membrane fractionation, KD/OE in vitro and in vivo Cancer letters High 37277019
2014 ERG oncoprotein binds to the ANXA2 promoter and transcriptionally represses ANXA2 expression; ERG-mediated ANXA2 repression disrupts apical ANXA2 localization, actin bundling at cell-cell junctions, and epithelial polarity, and promotes EMT through inhibition of CDC42 and RHOA and activation of cofilin. ERG siRNA knockdown, ChIP (ERG recruitment to ANXA2 promoter), ANXA2 localization imaging, small GTPase activity assays, IHC in clinical specimens Molecular cancer research : MCR High 25344575
2017 ANXA2 interacts with HGF/IGF-1-activated receptor signaling to increase its own phosphorylation, which contributes to EMT and TKI resistance in NSCLC cells. Proteomics, siRNA knockdown, in vitro/in vivo functional assays, dual inhibition of c-met/IGF-1R Biochimica et biophysica acta. Molecular basis of disease Medium 29253515
2018 Anxa2 gene silencing attenuates obesity-induced insulin resistance by inhibiting p50 nuclear translocation of the NF-κB signaling pathway, resulting in reduced inflammatory cytokines and improved glucose tolerance. Anxa2 siRNA knockdown in HFD mouse model and palmitic acid-induced IR cell model, glucose tolerance test, Western blot for NF-κB pathway components American journal of physiology. Cell physiology Medium 30462534
2022 p-STAT3 binds to the Anxa2 promoter and promotes its transcription; elevated ANXA2 then activates Caspase-1-mediated hepatocyte pyroptosis and fibrosis in NASH, forming a p-STAT3/ANXA2/Caspase-1 axis. ChIP-Seq for STAT3 occupancy at Anxa2 promoter, ANXA2 overexpression rescue after p-STAT3 inhibition, Caspase-1 specific inhibition, in vivo NASH mouse model Journal of translational medicine High 36324154
2024 ANXA2 upregulates the phosphorylation of HSF1 via MTORC2, leading to transcriptional activation of ATG7, which drives autophagy and promotes chemoresistance in triple-negative breast cancer cells. HSPA (Hsp70) interacts with ANXA2 to protect it from lysosomal proteolysis. ChIP (HSF1 at ATG7 promoter), MTORC2 inhibition, bafilomycin A1 autophagic flux assay, Co-IP, TNBC xenograft mouse model Autophagy High 38290972
2015 VvpE (Vibrio vulnificus elastase) induces recruitment of NADPH oxidase 2 into membrane lipid rafts coupled with ANXA2, facilitating ROS production that activates NF-κB, leading to IL-1β production and necrosis in intestinal epithelial cells; ANXA2 knockdown reduces VvpE-induced necrotic cell death. siRNA knockdown of ANXA2, lipid raft fractionation, ROS measurement, NF-κB reporter assay Journal of immunology Medium 26223656
2023 ANXA2 interacts with the lipoyl-binding domain of DBT (dihydrolipoamide branched chain transacylase E2) to activate Hippo signaling, leading to decreased nuclear YAP localization and transcriptional repression of lipogenic genes in clear cell renal cell carcinoma. Immunoprecipitation, mass spectrometry, mutational studies, luciferase reporter assay, nuclear fractionation Cancer communications Medium 36860124
2024 TIM-4 interacts with ANXA2 to promote PI3K/AKT pathway activation and L-OPA1 protein expression, thereby enhancing mitochondrial fusion and OXPHOS in lung cancer cells. Co-immunoprecipitation, TIM-4 KD/OE, OXPHOS inhibition (rescue), Western blot for PI3K/AKT/OPA1 Cell death & disease Medium 36806050
2019 ANXA2 promotes miR155HG expression via STAT3 phosphorylation binding to the miR155HG promoter, while miR155HG sponges miR-185 to increase ANXA2 expression, forming a miR155HG/miR-185/ANXA2 positive feedback loop in glioblastoma. Luciferase reporter assay, ChIP, Western blot, siRNA knockdown, intracranial GBM mouse model Journal of experimental & clinical cancer research : CR Medium 30898167
2024 Hspb1 directly interacts with Anxa2 to decrease its aggregation and phosphorylation; through Anxa2, Hspb1 enables Prdx1 to maintain antioxidative activity by decreasing Thr-90 phosphorylation of Prdx1, thereby protecting pancreatic acinar cells from apoptosis and ferroptosis in severe acute pancreatitis. Hspb1 KO mice, Anxa2 KO mice, acinar-specific Prdx1 KO mice, Co-IP, phosphorylation assays, AAV8-Hspb1 treatment International journal of biological sciences High 38481805
2024 A novel m7G-modified tsRNA (mtiRL) specifically binds ANXA2 to promote its Tyr24 phosphorylation by enhancing the ANXA2-Yes1 interaction, leading to ANXA2 activation and increased nuclear localization in bladder cancer cells. m7G small RNA-modified chip, siRNA/overexpression functional assays, Co-IP for ANXA2-Yes1 interaction, phospho-mutant studies, in vivo models Advanced science Medium 38894581
2022 FOXD1 induces RalA expression by directly binding the RalA promoter; RalA then forms a complex with ANXA2 and Src, promoting the ANXA2-Src interaction and increasing Tyr23 phosphorylation of ANXA2, which activates ERK1/2 signaling to enhance breast cancer CTC formation and metastasis. ChIP-seq, CUT&Tag-seq, GST-pulldown, Co-IP, RalA-GTP inhibition, in vivo CTC counting, ERK1/2 inhibitor treatment Journal of experimental & clinical cancer research : CR High 36229838
2023 METTL3 reduces ANXA2 expression in T lymphocytes through m6A modification, thereby inhibiting p38MAPK/MMP-9 pathway activation; inhibition of ANXA2 in T lymphocytes reduces their migration to the ischemic brain and confers neuroprotection in ischemic stroke. m6A sequencing/modification assay, METTL3 overexpression, shRNA KD of ANXA2 and METTL3, MCAO in vivo model, OGD/R neuronal model FASEB journal Medium 37249328
2024 USP4 interacts with ANXA2, deubiquitinating it by cleaving Lys48- and Lys63-linked polyubiquitin chains; Lys63-linked polyubiquitin of ANXA2 K28 mediates Y24 phosphorylation. K10 acetylation of ANXA2 enhances its interaction with USP4. USP4/ANXA2 promotes glioblastoma stem cell maintenance and radioresistance via BMX-mediated STAT3 activation. Co-IP, ubiquitination site mass spectrometry, linkage-specific deubiquitination assays, K28 and K10 mutants, chromatin IP for H3K18 lactylation Cell death and differentiation High 40185997
2024 ADAM8 binds to ANXA2 and promotes phosphorylation of ANXA2 at Ser26; ADAM8 deficiency impedes ANXA2 Ser26 phosphorylation and inhibits mTOR Ser2448 phosphorylation, thereby activating autophagy and promoting cardiac repair after myocardial infarction. Macrophage-specific ADAM8 KO mice, Co-IP/MS, ANXA2 phosphorylation activation/inactivation rescue, RNA-seq, bone marrow transplantation Journal of advanced research High 39097092
2024 PFN1 (profilin-1) interacts with ANXA2 and recruits Src to promote ANXA2 phosphorylation, which then activates STAT3 transcription factor to induce vascular smooth muscle cell phenotype switching and neointimal hyperplasia. Co-IP, single-cell RNA sequencing, SMC-specific KO mice, Western blot for p-ANXA2/STAT3 Arteriosclerosis, thrombosis, and vascular biology Medium 39508106
2024 USP10 deubiquitinates MOF at lysine 410 to stabilize MOF; stabilized MOF promotes H4K16ac enrichment at the ANXA2 promoter in a JUN-dependent manner to stimulate ANXA2 transcription, which activates Wnt/β-catenin signaling in esophageal squamous cell carcinoma. Co-IP, deubiquitination assay, ChIP for H4K16ac at ANXA2 promoter, luciferase reporter, KD/OE in vitro and in vivo Oncogene High 38317006
2021 ETV4 transcription factor binds to the ANXA2 promoter and elevates ANXA2 expression at the transcriptional level; ANXA2 overexpression reverses sh-ETV4 inhibitory effects on HBV-infected liver cancer cell malignancy by activating Wnt/β-catenin pathway. ChIP, dual-luciferase reporter assay, ETV4 inhibition/overexpression rescue experiments Journal of biochemistry Medium 34347084
2017 ANXA2 R1 domain (repeat-one) inhibits PCSK9 by binding to it, blocking PCSK9-mediated LDL receptor degradation; the coding SNP V98L (rs17845226) in ANXA2-R1 is associated with ~18.8% higher LDL-C levels in humans. Genetic association study (NPHSII and UCLEB cohorts), eQTL analysis, allele-specific protein binding assay, reporter gene expression assay Atherosclerosis Medium 28456096
2024 NINJ1 activates TLR4 signaling by competitively binding ANXA2, which is an inhibitory interacting protein of TLR4, thereby enhancing macrophage infiltration and NF-κB/CCR2-mediated pro-inflammatory responses in abdominal aortic aneurysm. Protein-protein interaction analysis, macrophage-specific NINJ1 KO mice (CRISPR/Cas9), Co-IP, functional macrophage adhesion/migration assays, RNA-seq Advanced science Medium 38922800
2023 HDAC9 deacetylates ANXA2, which inhibits ubiquitinated ANXA2 degradation; elevated ANXA2 stability in hippocampal neurons mediates depression-like behavior. IP-MS to identify ANXA2 as HDAC9 substrate, HDAC9 KO/KD in hippocampal neurons, in vivo CRS depression model Cellular and molecular life sciences : CMLS Medium 37690046
2019 ANXA2 silencing inhibits proliferation, invasion, and migration in gastric cancer cells, establishing a functional role for ANXA2 in gastric cancer cell motility. Lentivirus-mediated ANXA2 knockdown, MTT, colony formation, flow cytometry, Transwell assay Journal of oncology Low 31186633
2016 ANXA2 knockdown in HCC cells reduces cell proliferation and motility, enhances apoptosis, suppresses pseudopodia/filopodia formation, and inhibits F-actin, β-tubulin expression, and Lamin B organization, indicating ANXA2 regulates cancer cell motility by remodeling cytoskeletal structures. RNAi knockdown, fluorescence microscopy, confocal microscopy, electron microscopy, apoptosis assay Micron (Oxford, England : 1993) Medium 27060670
2024 MUC5AC interacts with ANXA2, activating downstream matrix metalloproteases and facilitating extracellular matrix degradation to promote brain metastasis; disrupting MUC5AC-ANXA2 signaling with a peptide inhibitor abrogates the metastatic process. Immunoprecipitation, proteomic analysis, peptide inhibitor treatment, in vivo intracardiac injection brain metastasis model Experimental & molecular medicine Medium 38825648
2024 Microplastics bind to ANXA2 and are endocytosed into breast cancer cells via ANXA2-mediated endocytosis, causing mitochondrial damage, inducing mitophagy, and inhibiting IL-17 exocytosis. MPs pulldown experiments, mass spectrometry, siRNA/OE functional assays, mitophagy assay Environmental pollution Low 39557355
2025 USP10 deubiquitinates XAB2 at K593 (K48-linked polyubiquitination) to stabilize XAB2; XAB2 then binds the ANXA2 promoter to upregulate ANXA2 transcription, which promotes DNA damage repair and oxaliplatin resistance in colorectal cancer. Co-IP, mass spectrometry, ChIP-qPCR, dual-luciferase reporter assay, ubiquitin assay with site-specific mutagenesis Journal of experimental & clinical cancer research : CR High 40069750

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2017 Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a. Cancer research 206 28947421
2000 Characterization of an extracellular lipase encoded by LIP2 in Yarrowia lipolytica. Journal of bacteriology 125 10781549
2017 Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling. Biochimica et biophysica acta. Molecular basis of disease 120 29253515
2018 Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy 114 29172997
2013 Membrane-bound RLCKs LIP1 and LIP2 are essential male factors controlling male-female attraction in Arabidopsis. Current biology : CB 108 23684977
2019 The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. Journal of experimental & clinical cancer research : CR 106 30898167
2021 Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p/ANXA2 axis. Journal of translational medicine 102 33407563
2017 Circular RNA profiling reveals that circular RNAs from ANXA2 can be used as new biomarkers for multiple sclerosis. Human molecular genetics 96 28651352
2000 Autocloning and amplification of LIP2 in Yarrowia lipolytica. Applied and environmental microbiology 86 10919782
2015 Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells. Oncotarget 82 26307676
2020 S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Gut 73 31919231
2018 Annexin A2 overexpression associates with colorectal cancer invasiveness and TGF-ß induced epithelial mesenchymal transition via Src/ANXA2/STAT3. Scientific reports 70 30050103
2021 EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis. Oncogene 67 33941853
2021 LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2. Cancer immunology, immunotherapy : CII 66 34562123
2018 TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation. Cancer letters 66 30075204
2011 Peripheral blood monocyte-expressed ANXA2 gene is involved in pathogenesis of osteoporosis in humans. Molecular & cellular proteomics : MCP 59 21817168
2018 Long non-coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma. Journal of cellular and molecular medicine 56 30588744
2019 Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism. Cancer biology & medicine 55 31908887
2013 P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochemical pharmacology 55 24239898
2022 LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. Cell death & disease 54 35977942
2012 Up-regulation of Anxa2 gene promotes proliferation and invasion of breast cancer MCF-7 cells. Cell proliferation 53 22452352
2019 Ahnak scaffolds p11/Anxa2 complex and L-type voltage-gated calcium channel and modulates depressive behavior. Molecular psychiatry 51 30760886
2019 NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation. Theranostics 51 31695759
2019 lncRNA LINC00460 Silencing Represses EMT in Colon Cancer through Downregulation of ANXA2 via Upregulating miR-433-3p. Molecular therapy. Nucleic acids 51 32069703
2006 Purification and biochemical characterization of the LIP2 lipase from Yarrowia lipolytica. Biochimica et biophysica acta 51 17270492
2019 S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-κB positive feedback loop. Journal of cellular and molecular medicine 50 31430050
2004 Reactivity of pure Candida rugosa lipase isoenzymes (Lip1, Lip2, and Lip3) in aqueous and organic media. influence of the isoenzymatic profile on the lipase performance in organic media. Biotechnology progress 50 14763825
2023 N6-methyladenosine-modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis-regulated Hippo pathway. Cancer communications (London, England) 46 36860124
2017 miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 46 28609840
2017 Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells. Breast cancer research and treatment 45 28470457
2020 Interference of Hsa_circ_0003928 Alleviates High Glucose-Induced Cell Apoptosis and Inflammation in HK-2 Cells via miR-151-3p/Anxa2. Diabetes, metabolic syndrome and obesity : targets and therapy 42 32982348
2014 Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis. Medical oncology (Northwood, London, England) 40 25476478
1993 Biosynthesis of lipoic acid: characterization of the lipoic acid auxotrophs Escherichia coli W1485-lip2 and JRG33-lip9. Biochemistry 39 8466915
2019 Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells. Breast cancer research : BCR 38 31113450
2024 ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells. Autophagy 35 38290972
2023 TIM-4 orchestrates mitochondrial homeostasis to promote lung cancer progression via ANXA2/PI3K/AKT/OPA1 axis. Cell death & disease 35 36806050
2022 The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis. Journal of translational medicine 35 36324154
2009 Anx2 interacts with HIV-1 Gag at phosphatidylinositol (4,5) bisphosphate-containing lipid rafts and increases viral production in 293T cells. PloS one 34 19325895
2022 Hypoxia-induced circADAMTS6 in a TDP43-dependent manner accelerates glioblastoma progression via ANXA2/ NF-κB pathway. Oncogene 33 36396726
2016 Deciphering how LIP2 and POX2 promoters can optimally regulate recombinant protein production in the yeast Yarrowia lipolytica. Microbial cell factories 33 27651221
2012 Improving the thermostability of lipase Lip2 from Yarrowia lipolytica. Journal of biotechnology 33 22982168
2024 Hspb1 protects against severe acute pancreatitis by attenuating apoptosis and ferroptosis via interacting with Anxa2 to restore the antioxidative activity of Prdx1. International journal of biological sciences 32 38481805
2019 High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma. Disease markers 31 30881525
2012 Constitutive expression of Yarrowia lipolytica lipase LIP2 in Pichia pastoris using GAP as promoter. Applied biochemistry and biotechnology 30 22246727
2011 Intracellular expression of Vitreoscilla hemoglobin improves production of Yarrowia lipolytica lipase LIP2 in a recombinant Pichia pastoris. Enzyme and microbial technology 30 22133436
2024 Proteomic analysis identifies HSP90AA1, PTK2B, and ANXA2 in the human entorhinal cortex in Alzheimer's disease: Potential role in synaptic homeostasis and Aβ pathology through microglial and astroglial cells. Brain pathology (Zurich, Switzerland) 29 38247340
2001 Purification and characterization of Lip2 and Lip3 isoenzymes from a Candida rugosa pilot-plant scale fed-batch fermentation. Journal of biotechnology 28 11090688
2001 The isolation and characterisation of a Saccharomyces cerevisiae gene (LIP2) involved in the attachment of lipoic acid groups to mitochondrial enzymes. FEMS microbiology letters 28 11356580
2024 A Novel tsRNA, m7G-3' tiRNA LysTTT, Promotes Bladder Cancer Malignancy Via Regulating ANXA2 Phosphorylation. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 27 38894581
2011 Efficient cell surface display of Lip2 lipase using C-domains of glycosylphosphatidylinositol-anchored cell wall proteins of Yarrowia lipolytica. Applied microbiology and biotechnology 27 21494864
2011 Isolation of a thermostable variant of Lip2 lipase from Yarrowia lipolytica by directed evolution and deeper insight into the denaturation mechanisms involved. Journal of biotechnology 27 21763359
2021 A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells. Carcinogenesis 26 32531042
2018 Anxa2 gene silencing attenuates obesity-induced insulin resistance by suppressing the NF-κB signaling pathway. American journal of physiology. Cell physiology 26 30462534
2018 The interaction between ANXA2 and lncRNA Fendrr promotes cell apoptosis in caerulein-induced acute pancreatitis. Journal of cellular biochemistry 26 30474876
2017 Annexin A2 (ANXA2) interacts with nonstructural protein 1 and promotes the replication of highly pathogenic H5N1 avian influenza virus. BMC microbiology 26 28893180
2023 Isoliquiritigenin alleviates the development of alcoholic liver fibrosis by inhibiting ANXA2. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 25 36680814
2016 Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells. International journal of molecular sciences 25 27754360
2022 FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer. Journal of experimental & clinical cancer research : CR 24 36229838
2021 The ANXA2/S100A10 Complex-Regulation of the Oncogenic Plasminogen Receptor. Biomolecules 24 34944416
2018 Biological Effect and Mechanism of the miR-23b-3p/ANXA2 Axis in Pancreatic Ductal Adenocarcinoma. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 24 30355917
2015 Vibrio vulnificus VvpE Stimulates IL-1β Production by the Hypomethylation of the IL-1β Promoter and NF-κB Activation via Lipid Raft-Dependent ANXA2 Recruitment and Reactive Oxygen Species Signaling in Intestinal Epithelial Cells. Journal of immunology (Baltimore, Md. : 1950) 23 26223656
2021 ETV4 mediates the Wnt/β-catenin pathway through transcriptional activation of ANXA2 to promote hepatitis B virus-associated liver hepatocellular carcinoma progression. Journal of biochemistry 22 34347084
2019 A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer. Journal of experimental & clinical cancer research : CR 22 31242951
2018 Anxa2 attenuates osteoblast growth and is associated with hip BMD and osteoporotic fracture in Chinese elderly. PloS one 22 29570731
2024 Stabilization of MOF (KAT8) by USP10 promotes esophageal squamous cell carcinoma proliferation and metastasis through epigenetic activation of ANXA2/Wnt signaling. Oncogene 21 38317006
2022 Characterization of Polymer Degrading Lipases, LIP1 and LIP2 From Pseudomonas chlororaphis PA23. Frontiers in bioengineering and biotechnology 21 35519608
2020 Circ-EEF2 facilitated autophagy via interaction with mir-6881-3p and ANXA2 in EOC. American journal of cancer research 21 33294264
2016 ANXA2 enhances the progression of hepatocellular carcinoma via remodeling the cell motility associated structures. Micron (Oxford, England : 1993) 21 27060670
2023 FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males. Cancer letters 20 37277019
2017 A new cis-acting motif is required for the axonal SMN-dependent Anxa2 mRNA localization. RNA (New York, N.Y.) 20 28258160
2015 RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway. Breast cancer research and treatment 20 26253946
2000 S100 protein-annexin interactions: a model of the (Anx2-p11)(2) heterotetramer complex. Biochimica et biophysica acta 20 11108962
2021 ANXA2 Facilitates Enterovirus 71 Infection by Interacting with 3D Polymerase and PI4KB to Assist the Assembly of Replication Organelles. Virologica Sinica 19 34196914
2019 ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells. Journal of oncology 19 31186633
2015 A novel Anxa2-interacting protein Ebp1 inhibits cancer proliferation and invasion by suppressing Anxa2 protein level. Molecular and cellular endocrinology 19 25917452
2005 Involvement of hexokinase Hxk1 in glucose catabolite repression of LIP2 encoding extracellular lipase in the yeast Yarrowia lipolytica. Current microbiology 19 15883872
2024 NINJ1 Facilitates Abdominal Aortic Aneurysm Formation via Blocking TLR4-ANXA2 Interaction and Enhancing Macrophage Infiltration. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 18 38922800
2019 Interaction of HE4 and ANXA2 exists in various malignant cells-HE4-ANXA2-MMP2 protein complex promotes cell migration. Cancer cell international 18 31210752
2017 Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene. Atherosclerosis 18 28456096
2025 USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer. Journal of experimental & clinical cancer research : CR 17 40069750
2025 Lactylation-driven USP4-mediated ANXA2 stabilization and activation promotes maintenance and radioresistance of glioblastoma stem cells. Cell death and differentiation 16 40185997
2023 Machine learning identifies ferroptosis-related gene ANXA2 as potential diagnostic biomarkers for NAFLD. Frontiers in endocrinology 16 38192427
2020 HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression. Biomolecules 16 32197509
2024 Dissecting the MUC5AC/ANXA2 signaling axis: implications for brain metastasis in lung adenocarcinoma. Experimental & molecular medicine 15 38825648
2007 High levels of the proNGF peptides LIP1 and LIP2 in the serum and synovial fluid of rheumatoid arthritis patients: evidence for two new cytokines. Journal of neuroimmunology 15 18162190
2023 METTL3-mediated ANXA2 inhibition confers neuroprotection in ischemic stroke: Evidence from in vivo and in vitro studies. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 14 37249328
2022 The mouse Anxa6/miR-9-5p/Anxa2 axis modulates TGF-β1-induced mouse hepatic stellate cell (mHSC) activation and CCl4-caused liver fibrosis. Toxicology letters 14 35483553
2012 Effect of ANXA2 gene single nucleotide polymorphism (SNP) on the development of osteonecrosis in Indian sickle cell patient: a PCR-RFLP approach. Indian journal of experimental biology 14 22822523
2024 ADAM8 deficiency in macrophages promotes cardiac repair after myocardial infarction via ANXA2-mTOR-autophagy pathway. Journal of advanced research 13 39097092
2024 m6A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway. Arteriosclerosis, thrombosis, and vascular biology 13 39508106
2022 2D transparent few-layered hydrogen substituted graphdiyne nano-interface for unprecedented ultralow ANXA2 cancer biomarker detection. Biosensors & bioelectronics 13 35696865
2022 Annexin A2 (ANXA2) regulates the transcription and alternative splicing of inflammatory genes in renal tubular epithelial cells. BMC genomics 13 35906541
2021 The S100A10-AnxA2 complex is associated with the exocytosis of hepatitis B virus in intrauterine infection. Laboratory investigation; a journal of technical methods and pathology 13 34645932
2019 High levels of ANXA2 are characteristic of malignant salivary gland tumors. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 13 31325182
2014 ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer. Molecular cancer research : MCR 13 25344575
2024 Microplastics accumulated in breast cancer patients lead to mitophagy via ANXA2-mediated endocytosis and IL-17 signaling pathway. Environmental pollution (Barking, Essex : 1987) 12 39557355
2023 Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours by inhibiting ANXA2 degradation. Cellular and molecular life sciences : CMLS 12 37690046
2021 Long noncoding RNA LINC00184 facilitates the proliferation, metastasis, and adenine metabolism of cholangiocarcinoma via modulating hsa-miR-23b-3p/ANXA2 axis. Environmental toxicology 12 33913242
2020 Important role of annexin A2 (ANXA2) in new blood vessel development in vivo and human triple negative breast cancer (TNBC) growth. Experimental and molecular pathology 12 32866522
2021 CircRNA ANXA2 Promotes Lung Cancer Proliferation and Metastasis by Upregulating PDPK1 Expression. Journal of oncology 11 34992655